No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IDXX IDEXX Laboratories Inc
- 475.290
- +7.090+1.51%
Close Jul 22 16:00 ET
- 475.290
- 0.0000.00%
Post 17:08 ET
39.25BMarket Cap46.06P/E (TTM)
479.300High466.980Low576.56KVolume474.900Open468.200Pre Close272.70MTurnover0.71%Turnover Ratio47.25P/E (Static)82.59MShares583.39052wk High25.02P/B38.83BFloat Cap372.50052wk Low--Dividend TTM81.70MShs Float706.950Historical High--Div YieldTTM2.63%Amplitude2.313Historical Low472.974Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
The Zacks Consensus Estimate for earnings is pinned at $2.87 per share, which implies a 7.5% rise from the year-ago reported figure.
Here's How Much $100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth Today
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 20 years by 3.33% on an annualized basis producing an average annual return of 11.73%. Currently, IDEXX Laboratories has a
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Maintains Target Price $589
Morgan Stanley analyst Erin Wright maintains $IDEXX Laboratories Inc(IDXX.US)$ with a buy rating, and maintains the target price at $589.According to TipRanks data, the analyst has a success rate of 6
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $589
Morgan Stanley analyst Erin Wright maintains $IDEXX Laboratories Inc(IDXX.US)$ with a buy rating, and adjusts the target price from $596 to $589.According to TipRanks data, the analyst has a success
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $589 From $596, Maintains Overweight Rating
IDEXX Laboratories (IDXX) has an average outperform rating and a price target range of $400 to $641, according to analysts polled by Capital IQ.Price: 484.01, Change: +1.31, Percent Change: +0.27
Shareholders Are Optimistic That IDEXX Laboratories (NASDAQ:IDXX) Will Multiply In Value
Comments
$SharkNinja(SN.US$ : “SharkNinja is actually a very, very good company that I think can still come down a little bit more because it’s got a high price-to-earnings multiple, in light of what I saw with Helen of Troy, which makes similar products.”
$IDEXX Laboratories Inc(IDXX.US$ : “Idexx Labs has to come on the show. That would make me feel better....I haven’t spoken to them in a long time.”
$Ready Capital(RC.US$ : “It does pay a goo...
$IDEXX Laboratories Inc(IDXX.US$ : “Idexx Labs has to come on the show. That would make me feel better....I haven’t spoken to them in a long time.”
$Ready Capital(RC.US$ : “It does pay a goo...
2
$Zoetis(ZTS.US$ bought a few days ago a bit lucky with this one but planning to hold for a few months
I was attracted by the wide moat of ZTS and the future prospects of pets care / animal care let's be real fertility rates are plummeting in almost all developed countries and instead of having kids people are adopting pets if you go to Korea they have more pets per household than kids I'm not even kidding so after learning of this trend I started a reasonable position in b...
I was attracted by the wide moat of ZTS and the future prospects of pets care / animal care let's be real fertility rates are plummeting in almost all developed countries and instead of having kids people are adopting pets if you go to Korea they have more pets per household than kids I'm not even kidding so after learning of this trend I started a reasonable position in b...
2
$IDEXX Laboratories Inc(IDXX.US$ 👀 Here's How Much You Would Have Made Owning
IDEXX Laboratories Stock In The Last 15 Years!
IDEXX Laboratories Stock In The Last 15 Years!
The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg